Orexo ABORXOF 34 PB Ratio is 1.89 as of Jun. 24, 2026, which is 46% below its 10-year median of 3.48. GuruFocus rates ORXOF with a GF Score™ of 34/100 and a GF Value™ of $0.68 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 922 Drug Manufacturers companies, Orexo AB ranks worse than 55.97% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-24), Orexo AB's share price is $2.10. Orexo AB's Book Value per Share for the quarter that ended in Mar. 2026 was $1.11. Hence, Orexo AB's PB Ratio of today is 1.89.
The historical rank and industry rank for Orexo AB's PB Ratio or its related term are showing as below:
ORXOF'
s PB Ratio Range Over the Past 10 Years
Min: 1.57 Med: 3.48 Max: 29.63
Current: 2.02
During the past 13 years, Orexo AB's highest PB Ratio was 29.63. The lowest was 1.57. And the median was 3.48.
ORXOF's PB Ratio is ranked worse than 55.97% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.88
vs ORXOF: 2.02
During the past 3 years, the average Book Value Per Share Growth Rate was 35.80% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Orexo AB was 136.80% per year. The lowest was -52.80% per year. And the median was 3.40% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Orexo AB PB Ratio Related Terms
Orexo AB PB Ratio Historical Data
* Premium members only.
The historical data trend for Orexo AB's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Orexo AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orexo AB PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orexo AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where Orexo AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Orexo AB's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Orexo AB (ORXOF) has a PB Ratio of 1.89 as of Jun. 24, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Orexo AB and its competitors. This is 46% below median its historical median of 3.48. Over the past decade, Orexo AB's PB Ratio has ranged from 1.57 to 29.63. According to the industry distribution chart, Orexo AB ranks #516 out of 922 companies in the Drug Manufacturers industry, placing it in the top 56%.
Is Orexo AB's PB Ratio too high?
Orexo AB's current PB Ratio of 1.89 is 46% below median its 10-year median of 3.48. Over the past 10 years, this metric has ranged from a low of 1.57 to a high of 29.63. The Drug Manufacturers industry median PB Ratio is 1.88. Orexo AB's value of 1.89 is 0.5% above this industry median. Based on the distribution chart, Orexo AB ranks #516 out of 922 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Orexo AB has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orexo AB's PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Orexo AB ranks #516 out of 922 companies for PB Ratio. This places Orexo AB in the lower half of its industry. The industry median PB Ratio is 1.88. Orexo AB's value of 1.89 is 0.5% above this benchmark. Historically, Orexo AB's own PB Ratio has ranged from 1.57 to 29.63 over the past decade. While the company's 10-year median is 3.48 vs. the industry median of 1.88, Orexo AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.88, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orexo AB's current PB Ratio of 1.89 is 0.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Orexo AB and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orexo AB's current PB Ratio is 1.89, which is 46% below median its own 10-year median of 3.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orexo AB stock overvalued right now?
Based on GuruFocus' analysis, Orexo AB (ORXOF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.68, compared to a current price of $2.10 — trading 208.8% above its estimated fair value. The current PB Ratio is 1.89, which is 46% below median its 10-year median of 3.48 and 0.5% above the Drug Manufacturers industry median of 1.88. Orexo AB's overall GF Score™ is 34/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Orexo AB (ORXOF), the current PB Ratio is 1.89 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orexo AB (ORXOF) Overvalued in 2026?
Based on GuruFocus' analysis, Orexo AB stock appears to be overvalued.
The current stock price of $2.10 is trading 208.8% above its estimated GF Value™ of $0.68.
GuruFocus considers Orexo AB to be Significantly Overvalued.
Key valuation signals for ORXOF:
PB Ratio: 1.89 (46% below median its 10-year median of 3.48)
GF Value™: $0.68 vs. price of $2.10 (208.8% above fair value)
Industry Position: 0.5% above the Drug Manufacturers median (#516 of 922)
No single metric tells the full story. See the ORXOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orexo AB is a Swedish pharmaceutical company dedicated to advancing treatments for severe diseases and life-saving rescue medications to meet future healthcare needs, developing improved medications based on proprietary drug delivery technologies. At the core of its innovation is AmorphOX, which improves bioavailability and stability for both large and small molecules. It has developed four drugs from concept to approval, including Zubsolv, Abstral, Edluar, and Diabact UBT. The company's current development efforts focus on AmorphOX, with projects in preclinical and clinical phases across multiple therapeutic areas. It operates through US Commercial and HQ & Pipeline, which generate maximum revenue, and operates in the US, EU, and UK generating maximum revenue, and the Rest of the World.
34GF Score
Get the complete analysis for ORXOF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORXOF has been successfully added to your 
